Advertisement - Members don't see this ad
A few months back we were arguing about this very thing here (hypofractionation in high-risk PCA). Thoughts?
Glad ASTRO is giving us more and more ammo which suggests acute toxicity is higher for hypofractionated RT for prostate than conventional, with no benefit in terms of disease control.
I will continue to present the data to my patients, and most (not all, note, but most) will continue to select the less-toxic treatment as they have been doing for years now. As I would do. Because I'm a laggard instead of a neophile, I guess.
With all due respect to our European colleagues, "We need to make your treatment a little more toxic because we want it to be cheaper for other people to able to be treated" is a dog that would not hunt over here in the colonies.